Shire Orphan Therapies GmbH / Bayer Pharma AG / Mediwound Germany Gmbh / uniQure biopharma B.V. / Eisai Ltd / ViroPharma / Genzyme Europe B.V. / Swedish Orphan Biovitrum International AB / Roche Registration Limited / FGK Representative Service GmbH / Gilead Sciences International Limited / Amgen Europe B.V. / Otsuka Novel Products GmbH / Medac GmbH / TMC Pharma Services Ltd. / Farmaceutici SpA / Meda AB / Novartis Europharm Ltd / Glaxo Group Ltd / Pharmaxis Pharmaceuticals Limited / Orphan Europe S.a.r.l. / ARIAD Pharma Ltd / Eaton / Shire Human Genetic Therapies AB / Takeda A/S / Janssen-Cilag International NV / Biomarin Europe Ltd / Merck Serono Europe Ltd / Gentium S.p.a. / InterMune UK Ltd. / Vertex Pharmaceuticals (U.K.) Limited / Actelion Registration Ltd / Celgene Europe Limited / Pfizer Ltd / / /
Event
Man-Made Disaster / /
Facility
Genzyme Europe B.V. NAGLAZYME N-acetylgalactosamine-4sulfatase INN / /
IndustryTerm
treatment of growth failure / treatment of Lambert-Eaton myasthenic syndrome / treatment of severe hepatic veno-occlusive disease / del sito web / treatment of patients with Hunter syndrome / treatment of seizures associated with Lennox Gastaut syndrome / treatment of cystic fibrosis / /